Sagent Pharmaceuticals’ heparin sodium injection approved

The FDA has approved nine presentations of heparin sodium injection from Sagent Pharmaceuticals. These presentations are latex-free and feature Sagent’s proprietary PreventIV Measures packaging and labeling which aids in the prevention of medication errors. PreventIV includes the use of a unique color for each total strength, easy to read drug name, concentration and fill volume, and cartons printed on all sides.

Heparin is an anticoagulant indicated for the prophylaxis and treatment of venous thrombosis and its extension; low-dose regimen for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; prophylaxis and treatment of pulmonary embolism; atrial fibrillation with embolization; diagnosis and treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); prevention of clotting in arterial and cardiac surgery; and prophylaxis and treatment of peripheral arterial embolism.

For more information call (866) 625-1618 or visit www.sagentpharma.com.